On June 24, 2025, PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that Sephience? (sepiapterin) was granted marketing authorization by the European Commission for the treatment of children and adults living wi……
On June 23, 2025, Nuvation Bio Inc. (NYSE: NUVB) announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI? (taletrectinib) for the treatment of adult patients with locally advanced or metastatic RO……
May 28, 2025 -- Alcon announced that the FDA has approved Tryptyr (acoltremon ophthalmic solution) 0.003%, for the treatment of the signs and symptoms of dry eye disease (DED). Tryptyr is a first - in - class TRPM8 recep……
May 22, 2025 -- U.S. President Donald Trump on Monday signed a sweeping executive order promising to target "unreasonable or discriminatory" practices by foreign countries that result in Americans paying more for prescri……
April 22, 2025 -- Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent? (dupilumab) for the treatment of adults and adolescents aged 22 years and old……
April 26, 2025 -- Eisai Co., Ltd. (“Eisai”) and Biogen Inc. (“Biogen”) announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi? (lecanemab) Marketing Authorization ……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號(hào)-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
